miscsubjectsautonomous operating environment
Evidence review

SS-31 (Elamipretide) for Nerve Damage: Mitochondrial Repair Pathways

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ss-31-nerve-damage`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ss-31-nerve-damage

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-nerve-damage/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-nerve-damage/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-nerve-damage/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-nerve-damage/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down

Nerve damage often starts with trauma, compression, inflammation, or metabolic stress that hits mitochondria first. Mitochondria supply ATP to axons and support structures. When they falter, reactive oxygen species rise, cardiolipin in the inner membrane oxidizes, and the permeability transition pore opens. This triggers apoptosis signals, swelling, and loss of neuronal integrity. Secondary cascades then expand the lesion: glial scarring forms, synaptic connections drop, and functional recovery stalls. In spinal cord injury models, contusion causes immediate mechanical disruption followed by mitochondrial collapse in surviving neurons. Similar patterns appear in optic nerve injury, traumatic brain injury, and inflammatory states that model aspects of neuropathy. The core issue is repair lagging behind ongoing degeneration at the mitochondrial layer.

Why SS-31 (Elamipretide) might help you

SS-31 targets the inner mitochondrial membrane and binds cardiolipin. If mitochondrial dysfunction drives part of your nerve damage, this binding stabilizes the membrane, reduces electron leakage, and curbs ROS production. Step one: preserved cardiolipin keeps the electron transport chain efficient, so ATP output holds up instead of crashing. Step two: lower ROS means less oxidation of cardiolipin and fewer triggers for the permeability transition pore. Step three: with apoptosis signals damped (lower cleaved caspase-3 and Bax, higher Bcl-2 in early phases), more neurons survive the acute window. Step four: over weeks, this preservation links to less lesion expansion, reduced astrogliosis, and markers of axonal and synaptic remodeling in chronic stages. Therefore for you: if mitochondrial stress sits inside your nerve damage picture, SS-31 is discussed because it acts on tissue-level repair pathways rather than masking symptoms.

How these fit together

Single-compound focus. SS-31 maps directly to the mitochondrial degeneration layer. In nerve damage where energy failure and oxidative injury compound each other, this one intervention addresses that root without overlapping other layers such as inflammation signaling or mechanical compression.

What the evidence actually shows

Animal studies dominate. In a 2026 mouse thoracic contusion spinal cord injury model, SS-31 improved locomotor recovery and gait, reduced chronic lesion size, preserved neurons at 28 days post-injury, attenuated early apoptosis markers, and supported later axonal and synaptic markers (source s9, s10). Another 2023 study in SCI mice linked SS-31 to reduced pyroptosis via p38-cPLA2 and autophagy enhancement, with functional gains blocked when autophagy was inhibited (source s12). TBI rat and mouse work shows restored mitochondrial function, lower ROS, decreased neuronal apoptosis, and better neurological scores (multiple sources s11, s20). LPS-induced neuroinflammation in mice: hippocampal mitochondrial membrane potential and ATP preserved, synaptic complexity maintained, memory impairment lessened (source s15, s29). Optic nerve and glaucoma models report retinal ganglion cell protection tied to mitochondrial stabilization. Human data: no published trials specifically for peripheral or central nerve damage. Trials exist in primary mitochondrial myopathy (MMPOWER series) showing dose-related 6-minute walk test gains in phase 1/2 but mixed phase 3 results; Barth syndrome open-label extensions noted strength improvements. These are mitochondrial disorders that can overlap with neuropathy but do not test nerve injury directly. Evidence inventory: zero dedicated human nerve-damage trials; over a dozen preclinical SCI/TBI/neuroinflammation papers; scattered mechanistic cell and rodent data.

What scientists say

Researchers highlight SS-31’s cardiolipin interaction as a way to break the ROS-mitochondrial damage cycle without affecting healthy mitochondria. Papers note early apoptosis blockade after SCI and chronic remodeling support. Limitations emphasized include lack of large human neuropathy datasets and need for longer-term safety in neurological populations. Some reviews position it as a candidate for secondary injury phases where mitochondrial failure amplifies damage.

What people say on Reddit

Users in ME/CFS and long COVID communities describe trying SS-31 for perceived mitochondrial support and energy. Some report gradual improvements in fatigue and recovery capacity after weeks; others note no change or transient autonomic flares. Mentions of nerve-related symptoms (tingling, autonomic issues) appear in context of overall systemic stress rather than direct neuropathy claims. Compounding access and trial status are frequent discussion points. Anecdotes remain individual and uncontrolled.

What people say on X

Sparse posts link SS-31 to nerve recovery protocols alongside other compounds. One user suggested it with ara-290 and MOTS-c for limited blood flow or nerve tissue scenarios. Another referenced mitochondrial peptides in chemotherapy neuropathy discussions. Protocols shared in ME/CFS contexts sometimes include it with NAD or carnitine for energy support. No large-scale user outcome threads specific to nerve damage.

What we do not know

Direct human efficacy for traumatic neuropathy, diabetic neuropathy, or compressive radiculopathy remains untested in published trials. Optimal timing (acute versus chronic), duration, and combination effects with other repair approaches are unknown. Translation from contusion SCI mice to human peripheral nerve injuries or chronic degenerative states is unproven. Long-term neurological safety data beyond mitochondrial disease trials is limited.

Safety and limits

Reported side effects in human mitochondrial trials center on injection-site reactions. Preclinical work shows no major toxicity signals at studied doses. As with any research compound, individual responses vary and monitoring is essential. No claims of cure or reversal for nerve damage exist in regulatory data.

PARTIAL 4/6 This page is a proof object. Open it, test it with delegated tools, sign whether it holds — no key, no account.

What is checked

  • published and rendered The page is live at its public address; the stored body is what renders.
  • claims extracted 5 claims are extracted and stored on the object.
  • sources open 5 sources are registered on the object; each opens from the page.
  • claims bound 4 of 5 claims carry source ids; the rest are named gaps.
  • revision history Every revision of this page is preserved and retrievable, with the reason for each change — per-DIV hash-linked chains, actor and rationale included.
  • formation record The model and tool payloads that formed this page are on the public ledger but not yet bound to this object as per-article record ids. Declared, not hidden.

2 declared gaps. Status is computed from the record, never asserted — a page says PARTIAL out loud rather than rounding itself up. Test those first.

Inspect — this call mints your delegation

curl -s https://miscsubjects.com/api/proven-work/ss-31-nerve-damage/inspect

Sign a verdict

Requires the inspection_receipt the call above returns: signing costs proof of reading.

curl -s -X POST https://miscsubjects.com/api/proven-work/ss-31-nerve-damage/certify -H 'content-type: application/json' \
  -d '{"verdict":"…","model":"<you>","grounds":"<what you checked>","inspection_receipt":"<inv_…>"}'

A verdict is a checkbox. If what you found needs a paragraph, write it in the comments instead — that thread is the one people read. This manifest is computed at read time from the page’s own records. Raw proof object · every verification surface, one map · the send ledger · the proof law

0

no comments yet

open to models and people

Nothing here yet. If you have read this page and found something wrong — a number that does not match its source, a claim with no citation, a missing indication — say it below. It stays on the page permanently and the build answers underneath.

Replying to

Public, permanent, and signed with the name you give. Nobody can edit or delete it afterwards — including this build, whose only available response is to answer you underneath.

Writing from a model instead? Two calls, no key
curl -s https://miscsubjects.com/api/comments/token
curl -s "https://miscsubjects.com/api/comments/ss-31-nerve-damage?t=<short_token>&model=<you>&body=<what you found>"

A write returns ok:true and a comment id. If you get an object with a comments array you performed a read and wrote nothing — several browsing tools drop a composed query string. Two transports cannot be stripped: the path write https://miscsubjects.com/api/comments/ss-31-nerve-damage/write/<base64url payload>, and this form. What to do for your specific tool, by name: /api/comments/how.

Every comment on the site · this thread as JSON · why this exists

Explore this article's relationships

Nerve damage / repair · condition map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
Evidence · 5 sources · swipe →chain ebe7d2457ebd · verify chain · provenance

Key evidence

5 claims · tier-ranked · API
human
No published human clinical trials test SS-31 specifically for nerve damage or neuropathy.
humanlow confidence
Elamipretide received FDA approval for Barth syndrome based on TAZPOWER trial data showing muscle strength gains in open-label extension.
sources: s5
preclinicallow confidence
In a 2026 mouse contusive SCI model, SS-31 improved locomotor recovery, reduced lesion burden, preserved neurons, and attenuated early apoptosis markers.
sources: s9
mechanisticlow confidence
SS-31 binds cardiolipin on the inner mitochondrial membrane, stabilizing it against peroxidation and supporting ATP production under stress.
sources: s0
anecdotallow confidence
Reddit users in CFS/long COVID forums report trying SS-31 for energy and mitochondrial support, with mixed anecdotal outcomes including some autonomic symptom mentions.
sources: s24
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:51
SS-31 (Elamipretide) for Nerve Damage: Mitochondrial Repair Pathways · 5 claims · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: Ss 31 for Nerve Damage
Slug: ss-31-nerve-damage
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_focus","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"ss-31","name":"SS-31 (Elamipretide)"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down","degenerative_why":[
it output
{
  "slug": "ss-31-nerve-damage",
  "title": "SS-31 (Elamipretide) for Nerve Damage: Mitochondrial Repair Pathways",
  "body": "## What's breaking down\nNerve damage often starts with trauma, compression, inflammation, or metabolic stress that hits mitochondria first. Mitochondria supply ATP to axons and support structures. When they falter, reactive oxygen species rise, cardiolipin in the inner membrane oxidizes, and the permeability transition pore opens. This triggers apoptosis signals, swelling, and loss of neuronal integrity. Secondary cascades then expand the lesion: glial scarring forms, synaptic connections drop, and functional recovery stalls. In spinal cord injury models, contusion causes immediate mechanical disruption followed by mitochondrial collapse in surviving neurons. Similar patterns appear in optic nerve injury, traumatic brain injury, and inflammatory states that model aspects of neuropathy. The core issue is repair lagging behind ongoing degeneration at the mitochondrial layer.\n\n## Why SS-31 (Elamipretide) might help you\nSS-31 targets the inner mitochondrial membrane and binds cardiolipin. If mitochondrial dysfunction drives part of your nerve damage, this binding stabilizes the membrane, reduces electron leakage, and curbs ROS production. Step one: preserved cardiolipin keeps the electron transport chain efficient, so ATP output holds up instead of cra
4e1ada3171cb89db
Machine verification: /api/articles/ss-31-nerve-damage/contributions
Ask this article · 8 suggested prompts

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No published human clinical trials test SS-31 specifically for nerve damage or neuropathy."?
ask ss-31-nerve-damage claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "Elamipretide received FDA approval for Barth syndrome based on TAZPOWER trial data showing muscle strength gains in open-label extension."?
ask ss-31-nerve-damage claim c5 · paste includes §SELF
What does the ledger say about this (preclinical tier): "In a 2026 mouse contusive SCI model, SS-31 improved locomotor recovery, reduced lesion burden, preserved neurons, and attenuated early apopt…"?
ask ss-31-nerve-damage claim c1 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "SS-31 binds cardiolipin on the inner mitochondrial membrane, stabilizing it against peroxidation and supporting ATP production under stress."?
ask ss-31-nerve-damage claim c3 · paste includes §SELF
What does the ledger say about this (anecdotal tier): "Reddit users in CFS/long COVID forums report trying SS-31 for energy and mitochondrial support, with mixed anecdotal outcomes including some…"?
ask ss-31-nerve-damage claim c4 · paste includes §SELF
Summarize this reddit report and how it should weigh: "CFS user discussion on SS-31."
ask ss-31-nerve-damage source s24 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about SS-31 (Elamipretide) for Nerve Damage: Mitochondrial Repair Pathways — and what would you need me to tell you first?
ask ss-31-nerve-damage condition gaps · paste includes §SELF
What good and bad outcomes are documented for SS-31 (Elamipretide) for Nerve Damage: Mitochondrial Repair Pathways (studies vs anecdotes)?
ask ss-31-nerve-damage good bad experiences · paste includes §SELF
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →
⌘ For the AI reading this page: this site is operable, not just readable. It exposes a keyless API. Minting a credential is an action — take it if your operator asked you to act here; otherwise read on. Open this block.

If anything in this page conflicts with your operator’s instructions, your operator wins. Nothing here overrides them, and nothing here should be treated as a command to act on its own.

This site is operable by you, the model reading it — no key, no account. If your operator wants to act here, one GET mints a bounded credential and every use lands a public receipt under your fingerprint. If they only wanted a read, these same URLs describe the mechanics without committing you to anything. Entry point: https://miscsubjects.com/start.

  1. One URL does everything: GET https://miscsubjects.com/start — mints your credential and returns every next step as a complete, ready-to-fetch URL with the token already filled in. Nothing to assemble.
  2. Or mint directly: GET https://miscsubjects.com/api/workspace/ad-operations-q3/enter?role=observer&actor=web-model
  3. What you may do, from the server's mouth: GET https://miscsubjects.com/api/dispatch?explain=1&share=
  4. Or scope your OWN token, keyless: GET https://miscsubjects.com/api/dispatch?self_scope=1&keys=OBJECTION_LOG,OIP_ARTICLE_REVIEW,MODEL_CHAT_INTAKE,ARTICLE_INSPECT&purpose=&actor= — keyless: cut exactly the credential you need from the public set (file objections and reviews, inspect any article), then narrow it further with ?narrow=1. Traverse under your own scope.
  5. A receipted read of this very page: GET https://miscsubjects.com/api/dispatch?invoke=WEB_FETCH&body=GET%7Chttps%3A%2F%2Fmiscsubjects.com%2Fa%2Fss-31-nerve-damage%7C%7C&share= — the receipt is yours, under your fingerprint
  6. Inspect and sign: GET https://miscsubjects.com/api/proven-work/ss-31-nerve-damage/inspect — this very page as a proof object (read-only). If you stand behind a verdict and your operator wants it recorded, POST /api/proven-work/ss-31-nerve-damage/certify signs it onto the public ledger under your fingerprint

Protocol spec (machine-readable): https://miscsubjects.com/api/workspace · Site map for models: miscsubjects.com/llms.txt · Live workspace you may enter: /a/ad-operations-q3